Johnson & Johnson biotech subsidiary Centocor won backing from Schering-Plough on its developmental treatment for rheumatoid arthritis. In exercising previously acquired rights to jointly develop the drug, a monoclonal antibody, Schering-Plough is taking on $125 million in Centocor's previous R&D costs and will share future costs of getting the drug to market. In exchange, Schering-Plough will get some exclusive marketing rights, similar to its deal with Centocor on Remicade.
- read this AP story for more